Fat emulsion could be new weapon against pesticide poisoning
NCT ID NCT04393103
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial aimed to see if adding intralipid (a fat emulsion given through a vein) to standard care could help people poisoned by organophosphorus compounds, which are found in some pesticides. The plan was to compare hospital stay length and death rates between 30 patients getting intralipid plus standard treatment and 30 getting standard treatment alone. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Intralipid (fat emulsion given intravenously)
- What this could lead to
- If it had worked, this could have pointed to a simple, widely available treatment to reduce hospital time and deaths from organophosphorus poisoning.
- What could go wrong
- The trial was withdrawn before enrolling anyone, so there is no data. Even if conducted, it was a small early-stage study, and results might not have been conclusive.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Started
-
Apr 2024
- Finished
-
Jan 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age group of 18-60 years who are exposed to organophosphorus compounds. * Clinical manifestations of organophosphorus toxidromes (hyper-salivation, lacrimation, sweating, urinary incontinence, di-arrhea, vomiting and abdominal pain). Exclusion Criteria: 1. Patient or relative in charge refusal. 2. Chronic renal or liver disease manifested by history, clinical and investigatory diagnosis. 3. Previous history of acute or chronic pancreatitis 4. Combined poisoning with non OP compounds 5. Asymptomatic patients. 6. Contraindications to intralipid emulsion as: * disturbances of normal fat metabolism such as patho-logic hyperlipemia manifested by history, clinical and investigatory diagnosis. * lipoid nephrosis manifested by history, clinical and investigatory diagnosis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Organophosphorus poisoning are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.